Lava Therapeutics Nv Expected To Post A Loss Of 25 Cents A Share: Earnings Preview

LAVA Therapeutics NV

15/08/2025 13:36

LAVA Therapeutics NV LVTX.OQ LVTX.O is expected to  show no change in quarterly revenue when it reports  results  for the period ending September 30 2025

​LSEG's mean analyst estimate for LAVA Therapeutics NV is for a loss of 25 cents per share.

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts had risen by about 7.5% in the last three months. ​

Wall Street's median 12-month price target for LAVA Therapeutics NV is $1.37, about 12.4% below its last closing price of $1.54

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Jun. 30 2025
-0.25
-0.26
-0.32
Missed
-24.7
Mar. 31 2025
-0.38
-0.38
-0.13
Beat
66
Dec. 31 2024
-0.21
-0.29
-0.14
Beat
52.5​
Sep. 30 2024
-0.35
-0.33
-0.46
Missed
-39.4
​​Jun. 30 2024
-0.37
-0.36
-0.31
Beat
13.9
Mar. 31 2024
-0.11
-0.12
-0.02
Beat
84​
Dec. 31 2023
0.33
-0.12
-0.24
Missed
-92
Sep. 30 2023
-0.49
-0.49
-0.34
Beat
30.6

This summary was machine generated August 15 at 12:36 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)